Shares of Fulgent Genetics Inc (NASDAQ:FLGT) have been given an average broker rating score of 1.50 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and one has given a strong buy rating to the company.

Brokers have set a one year consensus target price of $13.25 for the company and are expecting that the company will post $0.03 EPS for the current quarter, according to Zacks. Zacks has also assigned Fulgent Genetics an industry rank of 172 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research upgraded Fulgent Genetics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 22nd.

Fulgent Genetics (NASDAQ:FLGT) traded up 0.96% during mid-day trading on Thursday, reaching $10.55. The company’s stock had a trading volume of 8,524 shares. The firm’s market cap is $186.48 million. Fulgent Genetics has a 12-month low of $7.59 and a 12-month high of $13.90. The company has a 50-day moving average price of $10.98 and a 200-day moving average price of $10.65.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings data on Monday, February 27th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.04 by $0.01. The company earned $5.85 million during the quarter, compared to analysts’ expectations of $5.99 million. On average, equities research analysts expect that Fulgent Genetics will post $0.37 earnings per share for the current year.

A number of large investors have recently modified their holdings of the company. Monashee Investment Management LLC acquired a new stake in shares of Fulgent Genetics during the third quarter worth about $2,584,000. Laurion Capital Management LP acquired a new stake in shares of Fulgent Genetics during the third quarter worth about $277,000. Baker BROS. Advisors LP acquired a new stake in shares of Fulgent Genetics during the third quarter worth about $1,153,000. Finally, Putnam Investments LLC raised its stake in shares of Fulgent Genetics by 1.2% in the fourth quarter. Putnam Investments LLC now owns 374,700 shares of the company’s stock worth $4,335,000 after buying an additional 4,400 shares during the last quarter. Institutional investors and hedge funds own 13.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Zacks: Fulgent Genetics Inc (FLGT) Given Average Rating of “Buy” by Analysts” was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at http://www.watchlistnews.com/zacks-fulgent-genetics-inc-flgt-given-average-rating-of-buy-by-analysts/1206035.html.

About Fulgent Genetics

Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.

5 Day Chart for NASDAQ:FLGT

Get a free copy of the Zacks research report on Fulgent Genetics (FLGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Fulgent Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.